INDP (Indaptus Therapeutics) Buildings And Improvements: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INDP Indaptus Therapeutics Inc INDP
26 GF Score
Price $2.57
! 1 Warning Sign
View Full Analysis

What is Indaptus Therapeutics Buildings And Improvements?

Indaptus Therapeutics INDP +24.27% 26 Buildings And Improvements is $0.00 Mil as of Jun. 2026. GuruFocus rates INDP with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Indaptus Therapeutics Buildings And Improvements Historical Data

* Premium members only.

The historical data trend for Indaptus Therapeutics's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indaptus Therapeutics Buildings And Improvements Chart

Indaptus Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buildings And Improvements
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Indaptus Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
INDP
26GF Score
Indaptus Therapeutics Inc INDP
Buildings And Improvements is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indaptus Therapeutics Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.

What does a Buildings And Improvements of $0.00 Mil mean?
Indaptus Therapeutics (INDP) has a Buildings And Improvements of $0.00 Mil as of Jun. 2026. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on Indaptus Therapeutics and its competitors.
Is Indaptus Therapeutics' Buildings And Improvements too high?
Indaptus Therapeutics' current Buildings And Improvements is $0.00 Mil. Overall, Indaptus Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Indaptus Therapeutics' Buildings And Improvements compare to NRXP and TNYA?
Indaptus Therapeutics' Buildings And Improvements of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buildings And Improvements for a Biotechnology company?
A good Buildings And Improvements depends on the Biotechnology industry context. However, Buildings And Improvements should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buildings And Improvements mean?
A high Buildings And Improvements can signal that a stock is expensive relative to its fundamentals. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on Indaptus Therapeutics and its competitors. Indaptus Therapeutics's current Buildings And Improvements is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indaptus Therapeutics stock overvalued right now?
Indaptus Therapeutics (INDP) has a current Buildings And Improvements of $0.00 Mil. The current Buildings And Improvements is $0.00 Mil. Indaptus Therapeutics' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buildings And Improvements calculated?
Buildings And Improvements is calculated from a company's financial statements. For Indaptus Therapeutics (INDP), the current Buildings And Improvements is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Indaptus Therapeutics Business Description

Address 3 Columbus Circle 15th Floor, New York, NY, USA, 10019
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
26GF Score

Get the complete analysis for INDP

Buildings And Improvements is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.57
Price